S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
Log in
NASDAQ:TCON

TRACON Pharmaceuticals Stock Forecast, Price & News

$9.35
+0.35 (+3.89 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.96
Now: $9.35▼
$9.75
50-Day Range
$8.64
MA: $10.28▼
$11.65
52-Week Range
$0.95
Now: $9.35▼
$12.20
Volume988,493 shs
Average Volume577,100 shs
Market Capitalization$127.95 million
P/E RatioN/A
Dividend YieldN/A
Beta2.02
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead clinical stage products include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include DE-122, which is in randomized Phase IIa study for the treatment of wet AMD; TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I/II to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in a Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Santen Pharmaceutical Co. Ltd. for the development of carotuximab products for ophthalmology indications; Roswell Park Cancer Institute and Health Research Inc.; Case Western Reserve University; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
TRACON Pharmaceuticals logo

Headlines

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
February 25, 2021 |  finance.yahoo.com
TRACON to Report Fourth Quarter and Full Year 2020 Financial Results and Company Highlights on February 25, 2021
February 18, 2021 |  finance.yahoo.com
Thursday 1/28 Insider Buying Report: OVLY, TCON
January 28, 2021 |  nasdaq.com
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review
January 19, 2021 |  finance.yahoo.com
TRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
January 6, 2021 |  finance.yahoo.com
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab Oncology and 3D Medicines
December 30, 2020 |  finance.yahoo.com
TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering
December 29, 2020 |  finance.yahoo.com
TRACON Pharmaceuticals Announces $8.8 Million Registered Direct Offering
December 22, 2020 |  finance.yahoo.com
TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal Trial
December 10, 2020 |  finance.yahoo.com
3 Biotech Stocks to Buy on First Vaccine Approval Optimism
December 3, 2020 |  finance.yahoo.com
Is TRACON Pharmaceuticals (TCON) A Good Stock To Buy Now?
November 30, 2020 |  finance.yahoo.com
TRACON Announces Publication in Cancer Cell of Clinical Data that Provides Molecular Insight into the Mechanism of Action of TRC102 and Patient Populations Most Likely to Respond to Treatment
November 23, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TCON
Previous Symbol
CUSIPN/A
CIK1394319
Webwww.traconpharma.com
Phone858-550-0780
Employees19
Year FoundedN/A

Debt

Debt-to-Equity Ratio0.13
Current Ratio2.76
Quick Ratio2.76

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3 million
Price / Sales42.65
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.67 per share
Price / Book13.96

Profitability

EPS (Most Recent Fiscal Year)($7.47)
Net Income$-22,670,000.00
Net MarginsN/A
Return on Equity-273.66%
Return on Assets-84.56%

Miscellaneous

Outstanding Shares13,685,000
Market Cap$127.95 million
Next Earnings Date5/12/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

1.89 out of 5 stars

Medical Sector

99th out of 1,956 stocks

Biological Products, Except Diagnostic Industry

10th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
$9.35
+0.35 (+3.89 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TCON News and Ratings via Email

Sign-up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions

Is TRACON Pharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TRACON Pharmaceuticals stock.
View analyst ratings for TRACON Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than TRACON Pharmaceuticals?

Wall Street analysts have given TRACON Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but TRACON Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting TRACON Pharmaceuticals?

TRACON Pharmaceuticals saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 332,800 shares, a drop of 39.3% from the December 31st total of 548,000 shares. Based on an average daily trading volume, of 810,900 shares, the short-interest ratio is currently 0.4 days. Currently, 2.6% of the shares of the company are short sold.
View TRACON Pharmaceuticals' Short Interest.

When is TRACON Pharmaceuticals' next earnings date?

TRACON Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 12th 2021.
View our earnings forecast for TRACON Pharmaceuticals.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its earnings results on Thursday, February, 25th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.03.
View TRACON Pharmaceuticals' earnings history.

How has TRACON Pharmaceuticals' stock been impacted by Coronavirus?

TRACON Pharmaceuticals' stock was trading at $1.41 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TCON shares have increased by 563.1% and is now trading at $9.35.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for TCON?

2 equities research analysts have issued twelve-month price targets for TRACON Pharmaceuticals' shares. Their forecasts range from $12.00 to $24.00. On average, they anticipate TRACON Pharmaceuticals' share price to reach $18.00 in the next year. This suggests a possible upside of 92.5% from the stock's current price.
View analysts' price targets for TRACON Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are TRACON Pharmaceuticals' key executives?

TRACON Pharmaceuticals' management team includes the following people:
  • Dr. Charles P. Theuer, CEO, Pres & Director (Age 57, Pay $826.76k)
  • Mr. Scott B. Brown CPA, M.S., Chief Accounting Officer & Head of Fin. (Age 40, Pay $445.04k)
  • Mr. Mark C. Wiggins M.B.A., Chief Bus. Officer (Age 65, Pay $501.84k)
  • Ms. Bonne Adams, Exec. VP of Clinical Operations (Age 44)
  • Mr. Shahe Garabedian, Sr. VP & Head of Quality Assurance
  • Dr. James L. Freddo, Chief Medical Officer (Age 66)

Who are some of TRACON Pharmaceuticals' key competitors?

Some companies that are related to TRACON Pharmaceuticals include Harpoon Therapeutics (HARP), Fusion Pharmaceuticals (FUSN), Solid Biosciences (SLDB), Jounce Therapeutics (JNCE), AVROBIO (AVRO), Opthea (OPT), Freeline Therapeutics (FRLN), Cellular Biomedicine Group (CBMG), Outlook Therapeutics (OTLK), SQZ Biotechnologies (SQZ), Cardiff Oncology (CRDF), Innate Pharma (IPHA), Codiak BioSciences (CDAK), Aptose Biosciences (APTO) and Innate Pharma (IPHYF).
View all of TCON's competitors.

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Ikarian Capital LLC (19.85%), Opaleye Management Inc. (18.40%), BlackRock Inc. (2.38%), Renaissance Technologies LLC (1.24%), Bank of New York Mellon Corp (0.46%) and GSA Capital Partners LLP (0.34%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc and Saundra L Pelletier.
View institutional ownership trends for TRACON Pharmaceuticals.

Which major investors are selling TRACON Pharmaceuticals stock?

TCON stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Jane Street Group LLC, and Vigilare Wealth Management.
View insider buying and selling activity for TRACON Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying TRACON Pharmaceuticals stock?

TCON stock was bought by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Opaleye Management Inc., BlackRock Inc., Renaissance Technologies LLC, Bank of New York Mellon Corp, Price T Rowe Associates Inc. MD, and Wells Fargo & Company MN. Company insiders that have bought TRACON Pharmaceuticals stock in the last two years include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, and Saundra L Pelletier.
View insider buying and selling activity for TRACON Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $9.35.

How much money does TRACON Pharmaceuticals make?

TRACON Pharmaceuticals has a market capitalization of $127.95 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-22,670,000.00 in net income (profit) each year or ($7.47) on an earnings per share basis.

How many employees does TRACON Pharmaceuticals have?

TRACON Pharmaceuticals employs 19 workers across the globe.

What is TRACON Pharmaceuticals' official website?

The official website for TRACON Pharmaceuticals is www.traconpharma.com.

Where are TRACON Pharmaceuticals' headquarters?

TRACON Pharmaceuticals is headquartered at 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]


This page was last updated on 2/26/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.